Alpitatug
Based on 1 Customer Validation
Alpitatug (IMC 3C5) is a fully human monoclonal antibody and also a VEGFR3 inhibitor. Alpitatug blocks renal lymphangiogenesis, prevents the formation of tubulointerstitial lymphatic vessels, and reduces the number of lymphatic vessels in rats. Alpitatug does not alter the proteinuria level, inflammatory cell infiltration, fibrosis markers or renal function parameters in proteinuric rats. Alpitatug can be used in research related to proteinuric nephropathy and advanced solid tumors.
For research use only. We do not sell to patients.
- Purity: 99.13%
- CAS No.: 2921676-05-1
- Molecular Weight:145.30 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
KLK2/Kallikrein 2
Alpitatug (40 mg/kg; i.p.; three times per week; 6 weeks) significantly reduces lymphatic vessel number in healthy male Wistar rats without impacting renal inflammatory or fibrotic markers[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (3-month-old male, 180-200 g, chronic kidney disease induced by single tail vein injection of 1.8 mg/kg adriamycin)[1]
-
Dosage:40 mg/kg
-
Administration:i.p.; three times per week; 6 weeks
-
Result:Completely prevented tubulointerstitial lymphatic vessel formation in proteinuric rats, with a significant reduction in mean LV number compared to untreated proteinuric rats (P<0.001).
Reduced LV number in healthy treated rats compared to untreated healthy controls (P<0.001).
Showed no significant changes in proteinuria, body weight, blood pressure, heart rate, food/fluid intake, or creatinine clearance compared to untreated proteinuric rats.
Exhibited a non-significant trend toward reduced ED1-positive macrophages, no marked change in CD3-positive T-cell number, and no significant effects on α-SMA-positive myofibroblast accumulation, collagen III deposition, or interstitial fibrosis (PAS staining score).
Showed a near-significant reduction in collagen III (α1) mRNA expression, but no significant effects on collagen I (α1), TGF-β1, VCAM-1, MCP-1/CCL2, or osteopontin mRNA expression.
Showed no significant differences in total white blood count, lymphocytes, neutrophils, basophils, or eosinophils.
-
Animal Model:Wistar rats (3-month-old male, 180-200 g, healthy)[1]
-
Dosage:40 mg/kg
-
Administration:i.p.; three times per week; 6 weeks
-
Result:Significantly reduced mean LV number in healthy rats compared to untreated healthy controls (P<0.001).
Showed no significant changes in body weight, blood pressure, heart rate, food/fluid intake, or creatinine clearance compared to untreated healthy rats.
Exhibited a non-significant trend toward reduced ED1-positive macrophages, no marked change in CD3-positive T-cell number, and no significant effects on α-SMA-positive myofibroblast accumulation, collagen III deposition, or interstitial fibrosis (PAS staining score).
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
-
Immobilized Human Kallikrein can bind Alpitatug. The EC50 for this effect is 227.9 ng/mL. -
Flow cytometric analysis of 1.5×106 HT-29 cells with Alpitatug (HY-P990608, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2921676-05-1
-
Appearance Liquid
-
Molecular Weight 145.30 kDa
-
Color Colorless to light yellow
-
Synonyms
IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)